A comparison of oral and implant naltrexone outcomes at 12 months

Ross Colquhoun, BPsych(Hons); Donald Y-K. Tan, MBBS; Samantha Hull, BPsych(Hons)

doi:10.5055/jom.2005.0054

Authors

Ross Colquhoun, BPsych(Hons)
Donald Y-K. Tan, MBBS
Samantha Hull, BPsych(Hons)

DOI:

https://doi.org/10.5055/jom.2005.0054

Keywords:

naltrexone, implant, social support, compliance, opiate addiction

Abstract

Naltrexone’s current use has been limited by compliance. Subcutaneous implants would seem to offer a solution to this problem and improve long-term outcomes. The aim of the present study was to compare groups of patients who had received oral naltrexone or a naltrexone implant after detoxification and to follow their progress. Forty-one patients received an implant, and 42 patients received oral naltrexone. They were surveyed at one, three, six, and 12 months after detoxification. Their designated support person was also contacted to confirm the self-reports of the participants. Patients were compared on gender, age, and length of time since detoxification. Implant patients showed much higher abstinence rates, while those in both groups who were abstinent showed greater compliance to naltrexone (time spent in treatment) and attended more counseling sessions. Although the participants were not randomly allocated to each treatment condition, the preliminary evidence indicates that implants can improve compliance rates and outcomes.

Author Biographies

Ross Colquhoun, BPsych(Hons)

Grad Dip Counselling and Psychotherapy, Clinical Director, Addiction Treatment and Psychology Services, Broadway Healthcare, Broadway, NSW, Australia.

Donald Y-K. Tan, MBBS

Addiction Medicine Specialist, Fairfield, NSW, Australia

Samantha Hull, BPsych(Hons)

Child and Family Consultation Services, Farnham Hospital and Centre for Health, Farnham, United Kingdom.

References

Tennant FS, Rawson RA, Cohen AJ, et al.: Clinical experience with naltrexone in suburban opiate addicts. J Clin Psychiatr. 1984: 45: 42-45.

Meyer MC, Straugn AB, Lo M, et al.: Bioequivalence, doseproportionality and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatr. 1984; 45(9): 15-19.

Colquhoun RM: Trials of Naltrexone Implants in Australia. Unpublished, 2003.

Volavka J, Resnick RB, Kestenbaum RS, et al.: Short-term effects of naltrexone in 155 heroin addicts. Biol Psychiatry. 1976; 11: 679-685.

King AC, Volpicelli JR, Gunduz M, et al.: Naltrexone biotransformation and incidence of subjective side-effects: A preliminary study. Alcohol Clin Exp Res. 1997; 21(5): 906-909.

Perez M, Wall ME: A comparative study of oral, intravenous and subcutaneous administration of H-naltrexone to normal male volunteers. In Willette RE, Barnett G (Eds.): Naltrexone Research Monograph 28. Rockville, MD: National Institute on Drug Abuse, 1981.

Anton RE, Hogan I, Jalali B, et al.: Multiple family therapy and naltrexone in the treatment of opiate-dependence. Drug Alcohol Depend. 1981; 8: 157-168.

Azarian A, Papiasvilli A, Joseph H: A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR. J Addict Disord. 1994; 13: 35-52.

Bell JR, Young MR, Masterman SC, et al.: A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust. 1999; 171: 26-30.

Hulse GK, Basso MR: The association between naltrexone compliance and daily supervision. Drug Alcohol Rev. 2000; 19(1): 41-48.

Wodak A, Saunders JB, Mattick RP, et al.: Rapid opiate detoxification and naltrexone treatment: Past, present and future. Drug Alcohol Rev. 2001; 20(4): 349-350.

Gossop M, Green L, Phillips G: What happens to opiate addicts immediately after treatment: A prospective follow-up study. BMJ. 1987; 294: 227-232.

Comer SD, Collins ED, Kleber HD, et al.: Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl). 2002; 159: 351-360.

Caplehorn JR, Dalton MS, Haldar F, et al.: Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse. 1996; 31(2): 177-196.

See KL, Delucchi KL, Masson C, et al.: Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. JAMA. 2000; 283(10): 1303-1310.

Simpson DD: The relation of time spent in drug abuse treatment to posttreatment outcome. Am J Psychiatry. 1979; 136(11): 1449-1453.

Rawson RA, McCann MJ, Shoptaw SJ, et al.: Naltrexone for opioid dependence: Evaluation of a manualised psychosocial protocol to enhance treatment response. Drug Alcohol Rev. 2001; 20: 67-78.

Strang J, Bearn J, Gossop M: Opiate detoxification under anaesthesia [Editorial]. BMJ. 1997; 315; 1249-1250.

Shufman EN, Porat S, Witztum E, et al.: The efficacy of Naltrexone in preventing re-abuse of heroin after detoxification. Biol Psychiatry. 1994; 35: 935-945.

Colquhoun RM: Outcomes of a naltrexone treatment program for opiate dependency. New Horizons: Reducing Drug Harm in the New Millennium. Brisbane: Alcohol and Drug Foundation (Qld), 1999.

Woody GE, Luborsky L, McLellan A, et al.: Psychotherapy for opiate addicts. Does it help? Arch Gen Psychiatry. 1983; 40: 639-645.

Ziedonis DM, Kosten TR: Pharmacotherapy improves treatment outcomes in depressed cocaine addicts. J Psychoactive Drugs. 1991; 23: 417-425.

Hulse GK, Arnold-Reed DE, O’Neil G, et al.: Achieving longterm continuous blood naltrexone and 6 beta-naltrexol coverage following sequential naltrexone implants. Addict Biol. 2004; 9: 67-72.

Hulse GK, Basso, MR: Reassessing naltrexone maintenance as a treatment for illicit heroin users. Drug Alcohol Rev. 1999; 18(3): 263-269.